ROR1 and B-cell chronic lymphocytic leukemia: We noted a marked synergy between ROR1-targeted therapy and BCL2 inhibition utilizing the FDA-approved inhibitor venetoclax, a drug that has demonstrated efficacy in other malignancies such as CLL and acute myeloid leukemia (AML) as well as preliminary efficacy in SCLC models with high levels of BCL2 expression29–32.